Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3)
Based on 1 Customer Validation
Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) is a mouse-derived IgG2a κ type antibody agonist, targeting to mouse 4-1BB/CD137. Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) is a chimeric antibody of the original LOB12.3 antibody (HY-P990809). Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) contains the LALA-PG mutation region. Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) can be used for the researches of cancer, infection, immunology and neurological disease.
For research use only. We do not sell to patients.
- Purity : 98.44%
- Molecular Weight:145.96 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Mouse IgG2a (LALA-PG)
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
4-1BB/CD137
Gene ID
Accession
XP_850336.1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
in vivo activation of 4-1BB
Verified Bioactivity
-
Immobilized Mouse CD137 Protein, His Tag can bind Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3). The EC50 for this effect is 68.1 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 145.96 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (230 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)